KRAS and non-small cell lung carcinoma: The variation in study populations (e.g., stage IV or recurrent NSCLC, stage IV non-squamous NSCLC with or without KRAS mutations, and stage IV adenocarcinoma), treatment combinations (e.g., encorafenib, carboplatin, erlotinib, buparlisib, cisplatin or pemetrexed and hydroxychloroquine), and outcome measures (e.g., ORR, PFS, OS, DCR, and DOR) across the studies may impact the interpretation of results, limiting the generalizability of findings to broader patient populations.